Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis - Wikidata - awgldk - TriplyDB

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

http://www.wikidata.org/entity/Q35030418

about

Cancer and liver cirrhosis: implications on prognosis and management Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates Multidisciplinary management of hepatocellular carcinoma in clinical practice.GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.Evolving role of Sorafenib in the management of hepatocellular carcinoma.Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience.Methodological assessment of HCC literature Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives.Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.PharmGKB summary: sorafenib pathways.Hoarseness due to lymph node metastasis of hepatocellular carcinoma: A case report.Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.Systemic treatments for hepatocellular carcinoma: challenges and future perspectives Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma

P2860

Q28068579-DC4E37A2-1A17-498A-993B-B5DF47EE5DEC Q28079378-BEEA0526-C768-48FC-9108-8FE785F2BEDD Q33406591-C98FA3CF-D563-4A19-9C28-7DB1FD70DF3D Q33666679-8E7A01AD-A99A-44E9-8B47-BF3C6BB53A0F Q33733830-61749E61-BCA6-4AEA-B6F1-E425FA10865B Q33779864-76987E8B-9907-460A-B1F9-0BFA2F05982B Q35167764-555A57E5-E7CF-47D4-BA71-C977EDCEB39E Q35811557-8AABF5F3-02E0-43FD-B3C2-73FE034865FB Q36532133-C5EB6C31-2CEC-4F74-B3D0-AFEFCC55ACAA Q36963820-C496F2B8-D537-42B7-8CF0-D5E3167EDFF9 Q37017008-02372CD8-14C5-425C-ACBF-8AE4D621359B Q37031712-64E1F89D-E96F-4BDA-BAAB-BA0983243288 Q37252306-76F94BF4-1413-4142-9E16-2B0C5919ED65 Q37393627-DF93E24B-ADB2-4E68-AF7B-FCABD9212992 Q37722656-886EFF7F-F3A8-45EB-AF2F-069388A0D4B0 Q38864682-6E05A639-1A62-4208-8B35-2F3C26B2E654 Q42413853-EF3CA519-E949-4DC9-8C06-F5C9B24A3F93 Q55646454-EF5E93D9-E033-4D95-AD46-9B402C48E053 Q57301434-AE099CF5-9368-42DA-9684-816694A35E9F Q57816332-CF610ED3-0F61-4C76-8347-85F12F0C6FB6

P2860

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

http://www.wikidata.org/entity/Q35030418

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety and Efficacy of Sorafen ...... hild-Pugh A versus B Cirrhosis

@ast

Safety and Efficacy of Sorafen ...... hild-Pugh A versus B Cirrhosis

@en

type

label

Safety and Efficacy of Sorafen ...... hild-Pugh A versus B Cirrhosis

@ast

Safety and Efficacy of Sorafen ...... hild-Pugh A versus B Cirrhosis

@en

prefLabel

Safety and Efficacy of Sorafen ...... hild-Pugh A versus B Cirrhosis

@ast

Safety and Efficacy of Sorafen ...... hild-Pugh A versus B Cirrhosis

@en

P1433

Q35030418-922F1BEE-47C9-419A-9374-94F19C2C4029

P1476

Q35030418-8C757C58-E177-4A3D-83D6-3695349B78C9

P2093

Q35030418-14DCC078-0075-405B-A2F4-FA243F3F73E0

Q35030418-2629C304-1EF7-4396-B9F7-5D4CA0637C10

Q35030418-3447F917-F5D5-4244-8175-7F53B36FF96D

Q35030418-55023E60-3166-4D0B-8AAC-DA22591FA4E0

Q35030418-80AE7880-4773-4010-BEEB-BC4BF4AE44CA

Q35030418-84FFB0B6-5A3E-402F-86A8-FD4C30590BEF

Q35030418-85AEFB1A-7B89-4271-B78F-DCC6150A0A0E

Q35030418-8D826C7E-2EB6-4A49-943A-25358E304DBB

Q35030418-9FF7965F-7785-4A11-A551-B7CD00E2E2D5

Q35030418-C89F004F-B6BF-4529-9897-50B9C6CD008D

P2860

Q35030418-05B0F126-0852-4B67-8F9A-DAF00CB4DA0B

Q35030418-1A897667-C5BF-4CCC-93D8-6DEEFA1B75A4

Q35030418-759B1104-040A-4AD4-B4E5-81D03A25B9C9

Q35030418-C3CD1DB9-A791-49B9-92BF-33F073EF4B29

Q35030418-D3BD3673-F975-46FA-92B9-5F1992D1962B

Q35030418-EB91411F-ADB6-4DC7-A32F-6C993213A9B1

P304

Q35030418-D4AC199F-CB6B-4969-97C2-26D35663E95F

P31

Q35030418-0D3B4446-6D80-4E03-8B53-5CD97BD9291B

P433

Q35030418-93252DDA-7B59-4B41-A62C-9870E4161D92

P478

Q35030418-CD47102D-E16D-4820-955A-895F69D6058B

P577

Q35030418-8ADC2806-D2EF-412F-BDFE-8DDD86FCF1EB

P698

Q35030418-656E413F-EAAE-47CE-AD73-1CAC019254EF

P921

Q35030418-A39D2A63-43E2-488B-869A-F490317DD500

P932

Q35030418-61A040F5-9161-4793-BDC1-4297A8531B1F

P1433

Gastrointestinal cancer research : GCR

P1476

Safety and Efficacy of Sorafen ...... hild-Pugh A versus B Cirrhosis

@en

P2093

Arie Figer

http://www.w3.org/2001/XMLSchema#string

Armando Santoro

http://www.w3.org/2001/XMLSchema#string

Chetan Lathia

http://www.w3.org/2001/XMLSchema#string

Dimitris Voliotis

http://www.w3.org/2001/XMLSchema#string

Dino Amadori

http://www.w3.org/2001/XMLSchema#string

Ghassan K Abou-Alfa

http://www.w3.org/2001/XMLSchema#string

Jacques De Greve

http://www.w3.org/2001/XMLSchema#string

Marius Moscovici

http://www.w3.org/2001/XMLSchema#string

Sergio Ricci

http://www.w3.org/2001/XMLSchema#string

Sibyl Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

Transection of the oesophagus for bleeding oesophageal varices.

Drug glucuronidation in humans.

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

P304

40-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21673874

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

P932

3109886

http://www.w3.org/2001/XMLSchema#string